FDA Approves Livsayis™ (cemdisiran) for Adults Living with Generalized Myasthenia Gravis
The FDA has approved Livsayis™ (cemdisiran), developed by Regeneron Pharmaceuticals, as the first and only FDA-approved siRNA therapy for generalized myasthenia gravis (gMG) in anti-AChR antibody-positive patients. The subcutaneous treatment administered four times yearly targets complement component factor 5 (C5) to reduce immune-mediated damage at the neuromuscular junction, expanding therapeutic options for this chronic autoimmune neuromuscular disease.
